Should Xylem's (XYL) Strong Revenue and Smart Metering Momentum Prompt a Closer Look From Investors?

• Xylem announced its quarterly earnings results this week, highlighting stronger-than-expected revenue growth alongside improved organic revenue and EBITDA from ongoing operational efficiencies.
• Recent advisor commentary emphasized heightened demand in water infrastructure and the positive financial impact of cost synergies following Xylem’s Evoqua acquisition.
• We'll examine how expanding order momentum in smart metering shapes Xylem's investment narrative and expectations for sustainable growth.

The end of cancer? These 27 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

Xylem Investment Narrative Recap

To be a Xylem shareholder, you have to believe in growing long-term demand for water infrastructure, digital upgrades, and sustainable solutions, supported by resilient recurring revenue. The recent earnings report reinforced Xylem’s positive order momentum and operational efficiencies, but near-term performance will still be most sensitive to government infrastructure funding cycles; the latest results do not materially change this key catalyst or the risk of funding delays.

Among recent updates, Xylem’s new partnership with Amazon to deploy water-saving technology in Mexico’s largest cities illustrates the company’s ability to capture new digital infrastructure projects. This aligns closely with the growing adoption of smart metering, which remains central to its investment case as digital solutions increasingly drive order growth and earnings visibility.

However, despite robust headlines, investors should be aware that funding delays and unpredictability in major markets could still...

Read the full narrative on Xylem (it's free!)

Xylem's narrative projects $10.2 billion revenue and $1.4 billion earnings by 2028. This requires 5.2% yearly revenue growth and a $462 million earnings increase from $938.0 million.

Uncover how Xylem's forecasts yield a $158.67 fair value, a 7% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members offered four fair value estimates for Xylem shares, ranging widely from US$116 to US$159. While opinions differ, recent results highlight that government funding remains the primary swing factor for revenue and growth opportunities.

Explore 4 other fair value estimates on Xylem - why the stock might be worth as much as 7% more than the current price!

Build Your Own Xylem Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Xylem research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Xylem research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Xylem's overall financial health at a glance.

Curious About Other Options?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• We've found 17 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• Outshine the giants: these 27 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com